Thompson Siegel & Walmsley LLC Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thompson Siegel & Walmsley LLC raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 30.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 352,562 shares of the specialty pharmaceutical company's stock after purchasing an additional 81,988 shares during the period. Thompson Siegel & Walmsley LLC owned approximately 0.56% of Jazz Pharmaceuticals worth $43,365,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $7,201,000. Desjardins Global Asset Management Inc. purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $1,943,000. Kovack Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 347.1% in the 4th quarter. Kovack Advisors Inc. now owns 29,971 shares of the specialty pharmaceutical company's stock worth $3,686,000 after buying an additional 23,267 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Jazz Pharmaceuticals by 94.2% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company's stock worth $11,210,000 after buying an additional 44,414 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Jazz Pharmaceuticals by 558.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company's stock worth $41,780,000 after buying an additional 273,764 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 5,000 shares of the company's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares of the company's stock, valued at $4,016,369.85. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CAO Patricia Carr sold 1,936 shares of the company's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 5,000 shares of the company's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares of the company's stock, valued at $4,016,369.85. The disclosure for this sale can be found here. Insiders own 4.40% of the company's stock.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of research analyst reports. StockNews.com downgraded Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 2nd. Barclays lowered their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an "overweight" rating on the stock in a report on Friday, May 3rd. UBS Group lowered their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating on the stock in a report on Friday, March 1st. Truist Financial reaffirmed a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $195.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $192.75.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $3.49 during midday trading on Friday, reaching $109.63. 564,155 shares of the company's stock traded hands, compared to its average volume of 632,006. The company has a 50-day moving average price of $114.88 and a two-hundred day moving average price of $120.30. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. Jazz Pharmaceuticals plc has a 52 week low of $103.01 and a 52 week high of $146.70. The firm has a market capitalization of $6.91 billion, a PE ratio of 22.60, a price-to-earnings-growth ratio of 1.66 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. As a group, equities analysts anticipate that Jazz Pharmaceuticals plc will post 15.38 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.